CLAIM CARD
Within the curated corpus, the immune outcome class is represented by a single preclinical study, creating a tension between mechanistic promise and the absence of corroborating human data. No human clinical trials testing immune or inflammatory endpoints as primary outcomes for PCSK9 inhibitors were identified in this synthesis. Therefore, while the preclinical signal is positive and mechanistically coherent, the evidence base is too sparse to draw conclusions about immune-mediated longevity effects in humans. This represents a critical gap where the biological rationale is not yet matched by clinical investigation.
Evidence grade: exploratory
Contradiction status: none
Publication: 4753c82f-24d3-490c-8a23-6cc8d4194c24
Provenance: Derivation Web chain
Citation Support
source_1Ma 2025source_2Schwartz 2021source_3Lehrke 2024source_4Imran 2023source_5Faraidy 2023